Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194470 | 1.00 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL5697563 | 1.00 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL5425984 | 0.90 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL18512865 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL22261563 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL15810727 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL659090 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL659091 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805336 | 0.90 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL28738894 | 0.89 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361923-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100151458-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7695902-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629321-B2 | Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase) | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7432250-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432249-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | COOK PHILLIP D | 2007-10-04 | — | — | US | disclosed |
| EP-1621545-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1600506-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-0928290-B9 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20030096287-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | IONIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030096286-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030096784-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ISIS PHARMACEUTICALS, INC. | 2003-03-13 | — | — | US | disclosed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6222025-B1 | OLIGONUCLEOTIDES HAVING 2' AND 5 SUBSTITUTED PYRIMIDINE NUCLEOTIDES; INCREASED AFFINITY FOR NUCLEIC ACIDS; INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| US-6166197-A | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6107094-A | IN VITRO MODIFICATION OF TARGET RNA BY CONTACTING SOLUTION OF TARGET AND RIBONUCLEASE PREFERENTIAL FOR DOUBLE-STRANDED RNA WITH OLIGONUCLEOTIDE COMPLEMENTARY TO TARGET AND INCLUDING NUCLEOTIDES MODIFIED TO IMPROVE AFFINITY/SPECIFICITY | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | disclosed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | TYMS, RRM2, ATIC | LMNA 3653/4885MTOR 3991/4885ALDH1A1 1105/4885 |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ATIC, TYMS, RRM2 | LMNA 3797/4885MTOR 4007/4885ALDH1A1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.